Ulipristal acetate (CDB-2914) is an orally active, selective progesterone receptor modulator (SPRM) . Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma[1][2].